Plasma bradykinin and early diabetic nephropathy lesions in type 1 diabetes mellitus.
<h4>Objective</h4>To examine the association of bradykinin and related peptides with the development of diabetic nephropathy lesions in 243 participants with type 1 diabetes (T1D) from the Renin-Angiotensin System Study who, at baseline, were normoalbuminuric, normotensive and had normal...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2017-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://doi.org/10.1371/journal.pone.0180964 |
| _version_ | 1818666882776956928 |
|---|---|
| author | Kevin M Wheelock Jian Cai Helen C Looker Michael L Merchant Robert G Nelson Gudeta D Fufaa E Jennifer Weil Harold I Feldman Ramachandran S Vasan Paul L Kimmel Brad H Rovin Michael Mauer Jon B Klein CKD Biomarkers Consortium |
| author_facet | Kevin M Wheelock Jian Cai Helen C Looker Michael L Merchant Robert G Nelson Gudeta D Fufaa E Jennifer Weil Harold I Feldman Ramachandran S Vasan Paul L Kimmel Brad H Rovin Michael Mauer Jon B Klein CKD Biomarkers Consortium |
| author_sort | Kevin M Wheelock |
| collection | DOAJ |
| description | <h4>Objective</h4>To examine the association of bradykinin and related peptides with the development of diabetic nephropathy lesions in 243 participants with type 1 diabetes (T1D) from the Renin-Angiotensin System Study who, at baseline, were normoalbuminuric, normotensive and had normal or increased glomerular filtration rate (GFR).<h4>Design</h4>Plasma concentrations of bradykinin and related peptides were measured at baseline by quantitative mass spectrometry. All participants were randomly assigned at baseline to receive placebo, enalapril or losartan during the 5 years between kidney biopsies. Kidney morphometric data were available from kidney biopsies at baseline and after 5 years. Relationships of peptides with changes in morphometric variables were assessed using multiple linear regression after adjustment for age, sex, diabetes duration, HbA1c, mean arterial pressure, treatment assignment and, for longitudinal analyses, baseline structure.<h4>Results</h4>Baseline median albumin excretion rate of study participants was 5.0 μg/min, and mean GFR was 128 mL/min/1.73 m2. After multivariable adjustment, higher plasma concentration of bradykinin (1-8) was associated with greater glomerular volume (partial r = 0.191, P = 0.019) and total filtration surface area (partial r = 0.211, P = 0.010), and higher bradykinin (1-7) and hyp3-bradykinin (1-7) were associated with lower cortical interstitial fractional volume (partial r = -0.189, P = 0.011; partial r = -0.164, P = 0.027 respectively). In longitudinal analyses, higher bradykinin was associated with preservation of surface density of the peripheral glomerular basement membrane (partial r = 0.162, P = 0.013), and for participants randomized to losartan, higher hyp3-bradykinin (1-8) was associated with more limited increase in cortical interstitial fractional volume (partial r = -0.291, P = 0.033).<h4>Conclusions</h4>Higher plasma bradykinin and related peptide concentrations measured before clinical onset of diabetic nephropathy in persons with T1D were associated with preservation of glomerular structures, suggesting that elevations of these kinin concentrations may reflect adaptive responses to early renal structural changes in diabetic nephropathy. |
| first_indexed | 2024-12-17T06:11:36Z |
| format | Article |
| id | doaj.art-19eb20ea55884b679802c76a47f54cd1 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-17T06:11:36Z |
| publishDate | 2017-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-19eb20ea55884b679802c76a47f54cd12022-12-21T22:00:36ZengPublic Library of Science (PLoS)PLoS ONE1932-62032017-01-01127e018096410.1371/journal.pone.0180964Plasma bradykinin and early diabetic nephropathy lesions in type 1 diabetes mellitus.Kevin M WheelockJian CaiHelen C LookerMichael L MerchantRobert G NelsonGudeta D FufaaE Jennifer WeilHarold I FeldmanRamachandran S VasanPaul L KimmelBrad H RovinMichael MauerJon B KleinCKD Biomarkers Consortium<h4>Objective</h4>To examine the association of bradykinin and related peptides with the development of diabetic nephropathy lesions in 243 participants with type 1 diabetes (T1D) from the Renin-Angiotensin System Study who, at baseline, were normoalbuminuric, normotensive and had normal or increased glomerular filtration rate (GFR).<h4>Design</h4>Plasma concentrations of bradykinin and related peptides were measured at baseline by quantitative mass spectrometry. All participants were randomly assigned at baseline to receive placebo, enalapril or losartan during the 5 years between kidney biopsies. Kidney morphometric data were available from kidney biopsies at baseline and after 5 years. Relationships of peptides with changes in morphometric variables were assessed using multiple linear regression after adjustment for age, sex, diabetes duration, HbA1c, mean arterial pressure, treatment assignment and, for longitudinal analyses, baseline structure.<h4>Results</h4>Baseline median albumin excretion rate of study participants was 5.0 μg/min, and mean GFR was 128 mL/min/1.73 m2. After multivariable adjustment, higher plasma concentration of bradykinin (1-8) was associated with greater glomerular volume (partial r = 0.191, P = 0.019) and total filtration surface area (partial r = 0.211, P = 0.010), and higher bradykinin (1-7) and hyp3-bradykinin (1-7) were associated with lower cortical interstitial fractional volume (partial r = -0.189, P = 0.011; partial r = -0.164, P = 0.027 respectively). In longitudinal analyses, higher bradykinin was associated with preservation of surface density of the peripheral glomerular basement membrane (partial r = 0.162, P = 0.013), and for participants randomized to losartan, higher hyp3-bradykinin (1-8) was associated with more limited increase in cortical interstitial fractional volume (partial r = -0.291, P = 0.033).<h4>Conclusions</h4>Higher plasma bradykinin and related peptide concentrations measured before clinical onset of diabetic nephropathy in persons with T1D were associated with preservation of glomerular structures, suggesting that elevations of these kinin concentrations may reflect adaptive responses to early renal structural changes in diabetic nephropathy.https://doi.org/10.1371/journal.pone.0180964 |
| spellingShingle | Kevin M Wheelock Jian Cai Helen C Looker Michael L Merchant Robert G Nelson Gudeta D Fufaa E Jennifer Weil Harold I Feldman Ramachandran S Vasan Paul L Kimmel Brad H Rovin Michael Mauer Jon B Klein CKD Biomarkers Consortium Plasma bradykinin and early diabetic nephropathy lesions in type 1 diabetes mellitus. PLoS ONE |
| title | Plasma bradykinin and early diabetic nephropathy lesions in type 1 diabetes mellitus. |
| title_full | Plasma bradykinin and early diabetic nephropathy lesions in type 1 diabetes mellitus. |
| title_fullStr | Plasma bradykinin and early diabetic nephropathy lesions in type 1 diabetes mellitus. |
| title_full_unstemmed | Plasma bradykinin and early diabetic nephropathy lesions in type 1 diabetes mellitus. |
| title_short | Plasma bradykinin and early diabetic nephropathy lesions in type 1 diabetes mellitus. |
| title_sort | plasma bradykinin and early diabetic nephropathy lesions in type 1 diabetes mellitus |
| url | https://doi.org/10.1371/journal.pone.0180964 |
| work_keys_str_mv | AT kevinmwheelock plasmabradykininandearlydiabeticnephropathylesionsintype1diabetesmellitus AT jiancai plasmabradykininandearlydiabeticnephropathylesionsintype1diabetesmellitus AT helenclooker plasmabradykininandearlydiabeticnephropathylesionsintype1diabetesmellitus AT michaellmerchant plasmabradykininandearlydiabeticnephropathylesionsintype1diabetesmellitus AT robertgnelson plasmabradykininandearlydiabeticnephropathylesionsintype1diabetesmellitus AT gudetadfufaa plasmabradykininandearlydiabeticnephropathylesionsintype1diabetesmellitus AT ejenniferweil plasmabradykininandearlydiabeticnephropathylesionsintype1diabetesmellitus AT haroldifeldman plasmabradykininandearlydiabeticnephropathylesionsintype1diabetesmellitus AT ramachandransvasan plasmabradykininandearlydiabeticnephropathylesionsintype1diabetesmellitus AT paullkimmel plasmabradykininandearlydiabeticnephropathylesionsintype1diabetesmellitus AT bradhrovin plasmabradykininandearlydiabeticnephropathylesionsintype1diabetesmellitus AT michaelmauer plasmabradykininandearlydiabeticnephropathylesionsintype1diabetesmellitus AT jonbklein plasmabradykininandearlydiabeticnephropathylesionsintype1diabetesmellitus AT ckdbiomarkersconsortium plasmabradykininandearlydiabeticnephropathylesionsintype1diabetesmellitus |